CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 280 filers reported holding CRISPR THERAPEUTICS AG in Q2 2020. The put-call ratio across all filers is 1.18 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2024 | $2,868,854 | -15.2% | 42,090 | -22.1% | 0.02% | -35.7% |
Q4 2023 | $3,383,467 | +135.8% | 54,049 | +111.4% | 0.03% | +64.7% |
Q2 2023 | $1,435,051 | +141423.8% | 25,562 | +2.5% | 0.02% | -15.0% |
Q4 2022 | $1,014 | -99.9% | 24,949 | +4.4% | 0.02% | -41.2% |
Q3 2022 | $1,561,000 | +30.5% | 23,893 | +21.4% | 0.03% | +9.7% |
Q2 2022 | $1,196,000 | -23.7% | 19,682 | -21.2% | 0.03% | -16.2% |
Q1 2022 | $1,568,000 | -17.2% | 24,983 | -0.0% | 0.04% | +15.6% |
Q4 2021 | $1,894,000 | -20.5% | 24,987 | +17.4% | 0.03% | -17.9% |
Q3 2021 | $2,383,000 | -1.7% | 21,286 | +34.4% | 0.04% | -43.5% |
Q4 2020 | $2,425,000 | +315.2% | 15,841 | +126.9% | 0.07% | +176.0% |
Q3 2020 | $584,000 | +57.0% | 6,983 | +37.8% | 0.02% | +38.9% |
Q2 2020 | $372,000 | -22.0% | 5,067 | -55.0% | 0.02% | -58.1% |
Q1 2020 | $477,000 | -53.2% | 11,249 | -32.8% | 0.04% | -6.5% |
Q4 2019 | $1,019,000 | +159.3% | 16,733 | +94.4% | 0.05% | +253.8% |
Q1 2018 | $393,000 | – | 8,608 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 498,558 | $37,781,000 | 20.21% |
Ariose Capital Management Ltd | 37,900 | $2,872,000 | 6.78% |
EcoR1 Capital, LLC | 1,077,483 | $81,652,000 | 2.60% |
NEA Management Company, LLC | 1,590,002 | $120,490,000 | 2.44% |
ARK Investment Management | 9,087,868 | $688,679,000 | 2.08% |
NIA IMPACT ADVISORS, LLC | 62,609 | $3,876,000 | 2.06% |
Deuterium Capital Management, LLC | 18,000 | $1,364,000 | 2.02% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 108,200 | $8,192,000 | 1.82% |
PLUSTICK MANAGEMENT LLC | 50,000 | $3,789,000 | 1.76% |
Nikko Asset Management Americas, Inc. | 4,319,471 | $330,526,000 | 1.74% |